These findings suggest that pembrolizumab combined with platinum-based chemotherapy, without radiotherapy, might provide a feasible and promising alternative treatment strategy for patients with unresectable, locally advanced NSCLC with a PD-L1 TPS of 50% or higher.
[Articles] Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
The Lancet Oncology | | Akito Hata, Taira Ninomaru, Hideaki Okada, Yoshihito Kogure, Masahide Oki, Nobuyuki Katakami, Takashi Kijima, Toshihide Yokoyama, Hirotaka Matsumoto, Yuki Sato, Terufumi Kato, Shunichi Sugawara, Takeshi Sawada, Kenichi Yoshimura, Takashi Seto, Kazuhiko Nakagawa, Isamu Okamoto, Nobuyuki Yamamoto, West Japan Oncology Group
Topics: lung-cancer, blood-cancer, immunotherapy, chemotherapy, radiation, clinical-trials, research